research
∙
06/27/2023
On fixed and uncertain mixture prior weights
This paper focuses on the specification of the weights for the component...
share
research
∙
12/21/2022
Duration of and time to response in oncology clinical trials from the perspective of the estimand framework
Duration of response (DOR) and time to response (TTR) are typically eval...
research
∙
12/20/2021
The Predictive Individual Effect for Survival Data
The call for patient-focused drug development is loud and clear, as expr...
research
∙
10/01/2020
Estimands in Hematologic Oncology Trials
The estimand framework included in the addendum to the ICH E9 guideline ...
research
∙
08/12/2020
Principal Stratum Strategy: Potential Role in Drug Development
A randomized trial allows estimation of the causal effect of an interven...
research
∙
09/20/2019
Alternative Analysis Methods for Time to Event Endpoints under Non-proportional Hazards: A Comparative Analysis
The log-rank test is most powerful under proportional hazards (PH). In p...
research
∙
08/21/2019
Beyond p-values: a phase II dual-criterion design with statistical significance and clinical relevance
Background: Well-designed phase II trials must have acceptable error rat...
research
∙
08/20/2019
Bayesian leveraging of historical control data for a clinical trial with time-to-event endpoint
The recent 21st Century Cures Act propagates innovations to accelerate t...
research
∙
08/20/2019
